Abivax SA Sponsored ADR $ABVX Shares Sold by Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. lessened its holdings in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) by 5.4% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 691,973 shares of the company’s stock after selling 39,550 shares during the quarter. Abivax accounts for 8.3% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s portfolio, making the stock its 2nd largest position. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. owned 0.88% of Abivax worth $93,316,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the business. Deutsche Bank AG acquired a new stake in Abivax during the 4th quarter valued at approximately $103,154,000. Fox Run Management L.L.C. acquired a new stake in Abivax during the 4th quarter valued at approximately $339,000. LPL Financial LLC grew its stake in Abivax by 114.9% during the 4th quarter. LPL Financial LLC now owns 62,842 shares of the company’s stock valued at $8,475,000 after purchasing an additional 33,595 shares in the last quarter. CenterBook Partners LP acquired a new stake in Abivax during the 4th quarter valued at approximately $968,000. Finally, Arrowpoint Investment Partners Singapore Pte. Ltd. acquired a new stake in Abivax during the 4th quarter valued at approximately $200,000. Institutional investors and hedge funds own 47.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on ABVX shares. Morgan Stanley decreased their target price on Abivax from $145.00 to $132.00 and set an “overweight” rating for the company in a research report on Tuesday, June 2nd. BTIG Research reiterated a “buy” rating and issued a $150.00 target price on shares of Abivax in a research report on Tuesday, June 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Abivax in a research report on Monday, April 20th. Wall Street Zen upgraded Abivax from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Finally, Citizens Jmp lifted their target price on Abivax from $131.00 to $187.00 and gave the stock a “market outperform” rating in a research report on Tuesday, June 2nd. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $130.08.

Abivax Price Performance

NASDAQ:ABVX opened at $98.03 on Thursday. Abivax SA Sponsored ADR has a 12-month low of $5.69 and a 12-month high of $148.83. The firm has a market capitalization of $7.81 billion, a P/E ratio of -18.82 and a beta of 0.69. The business has a 50 day simple moving average of $116.59 and a 200 day simple moving average of $119.41.

Abivax (NASDAQ:ABVX) last released its quarterly earnings data on Friday, May 22nd. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.23. The company had revenue of $1.56 million for the quarter, compared to analyst estimates of $0.40 million. Research analysts anticipate that Abivax SA Sponsored ADR will post -3.4 EPS for the current fiscal year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.